Search results

  1. Jonathan Edwards

    IV IG: Intravenous immunoglobulin infusions

    What evidence is there for that? In particular when we have no evidence that it 'works' at all? The only solid indication for Ig supplementation is for immunodeficiency as fa as I am aware. And people with ME/CFS do not have Ig deficiency.
  2. Jonathan Edwards

    The itaconate shunt hypothesis

    I thought even Robert had given up the metabolic trap idea.
  3. Jonathan Edwards

    Miscellaneous Research Thread

    They seem to ave made the usual mistake of thinking that people are conscious, rather than cells. But they might discover something important about how cells report their consciousness.
  4. Jonathan Edwards

    Miscellaneous Research Thread

    That seems very mysterious. They used AI to prove that dead people were not conscious?
  5. Jonathan Edwards

    IV IG: Intravenous immunoglobulin infusions

    In ten years on this forum I have not heard of anyone saying IVIG made them better. There was a member on the old forum who swore by IVIG but I was never quite sure why. Adverse reactions are common. There are people with immunodeficiency who need it to stay alive and cannot get it and rip-off...
  6. Jonathan Edwards

    Fractional-order safe mental-health corridor modelling w/Matignon spectral analysis of post-pandemic fatigue-to-recovery dynamics 2026 Vijayalakshmi+

    We used to camp in a back field belonging to Monsieur Matignon near the Pyrenees in the 1960s. He made very impressive "Marc", probably 85% alcohol v/v that my father brought home for use on winter's evenings. There were bee-eaters over the field and nightjars over the hills behind. Probably...
  7. Jonathan Edwards

    UK North Wales - Living Well Service for ME/CFS and Long Covid, Betsi Calawadr University, Claire Jones

    One might almost say that the bastards don't want to get better?
  8. Jonathan Edwards

    Oxidative stress in ME/CFS

    Michael Maes has been going on about oxidative stress in ME/CFS for years. Others have invoked it. I remember it being all the rage 50 years ago. And never discovered why anybody was interested in it.
  9. Jonathan Edwards

    Evidence of White Matter Neuroinflammation in [ME/CFS]: A Diffusion-Based Neuroinflammation Imaging Study 2026 Yu et al

    I think there is a danger of going off on a wild goose chase in response to papers about things like oxidative stress and cell senescence. There are always a bunch of papers to support any speculation in this sort of area. On a broad front I don't think we have much reason to think there is...
  10. Jonathan Edwards

    Persistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID, 2026, Perez-Mazzali+

    My suspicion is that if you need this sort of complicated statistical analysis to show patterns you are very likely to pick out things by chance. I don't see any clear immunological story here.
  11. Jonathan Edwards

    Review Effectiveness of non-pharmacological interventions for fatigue in long term conditions: systematic review & network meta-analysis, 2026, Leaviss

    It is weird if you see it as a guide to good practice. But RoB2 was deliberately designed to weaken standards in order to make it easier for clinical trial units to make a living out of trials as far as I can see. These 'tools' are a nonsense.
  12. Jonathan Edwards

    CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial 2026 Muller et al

    T cells kill but the dead celll will likely be phagocytosed by a nearby macrophage. The body should not be allowing rogue cells to survive and proliferate in the first place. CD19 CAR T cells will kill unwanted B cells but they will also kill all the wanted B cells, which the body should not be...
  13. Jonathan Edwards

    CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial 2026 Muller et al

    Not sure what you mean by that. CAR T cell treatment is a means of killing unwanted cells using autologous t cells armed with antibody-like receptors rather than using soluble monoclonal antibodies. Te linked paper is about CAR macrophages.
  14. Jonathan Edwards

    "The Cost of Indifference: The sad and curious case of the chronic fatigue syndrome" (Quillette)

    There aren't any abnormalities much demonstrated in ME/CFS so far. The genetic risk factors revealed by DecodeME are the little we have to go on at present. Almost all of the folklore about ME/CFS as a multisystem disease etc. etc. is baseless. The history has also been manipulated. ME/CFS has...
  15. Jonathan Edwards

    Incidence age is bimodal for [ME/CFS], with higher severity burden for early onset disease, 2026, McGrath et al

    That is a a very interesting paper, if a bit hard to understand in detail.
  16. Jonathan Edwards

    ME/CFS Science Blog article - Immune findings in ME/CFS

    This is basic immunology stuff, but the question is whether it is relevant to ME/CFS at all. In all recognised autoimmune diseases there is an imprecise relationshp between antibody titres and pathogenicity but there is still a very obvious difference between normals and patients. In ME/CFS...
  17. Jonathan Edwards

    Managing Energy Levels in Academia: Expanding the Conversation on Long COVID Pacing Technologies, 2026, Girouard

    I understand that it may take a considerable time for each person with ME/CFS to find the best way of planning their day to optimise what they can achieve and to avoid setbacks. What I query is whether digital technologies are actually any use for doing this. I also query the assumption that it...
  18. Jonathan Edwards

    NHS England - E-learning Modules on ME/CFS

    But isn't this the central point? Charity representatives have been lobbying the Royal College of Physicians to ensure that all medics do this e-learning module. That seems to be the way doctors are supposed to learn about severe ME/CFS. Why would cancer and diabetes be under medical school...
  19. Jonathan Edwards

    Incidence age is bimodal for [ME/CFS], with higher severity burden for early onset disease, 2026, McGrath et al

    That makes about three thousand four hundred and seventy three of us.
Back
Top Bottom